Gadolinium toxicity and treatment

Add time:07/27/2019    Source:sciencedirect.com

Gadolinium based contrast agents (GBCAs) play an important role in the diagnostic evaluation of many patients. The safety of these agents has been once again questioned after gadolinium deposits were observed and measured in brain and bone of patients with normal renal function. This retention of gadolinium in the human body has been termed “gadolinium storage condition”. The long-term and cumulative effects of retained gadolinium in the brain and elsewhere are not as yet understood. Recently, patients who report that they suffer from chronic symptoms secondary to gadolinium exposure and retention created gadolinium-toxicity on-line support groups. Their self-reported symptoms have recently been published. Bone and joint complaints, and skin changes were two of the most common complaints. This condition has been termed “gadolinium deposition disease”. In this review we will address gadolinium toxicity disorders, from acute adverse reactions to GBCAs to gadolinium deposition disease, with special emphasis on the latter, as it is the most recently described and least known.

We also recommend Trading Suppliers and Manufacturers of gadolinium EDTA (cas 15213-88-4). Pls Click Website Link as below: cas 15213-88-4 suppliers

Prev:Synthesis, characterization and catalytic activity under homogeneous conditions of ethylene glycol substituted porphyrin manganese(III) complexes
Next:Synthesis and properties of gadolinium doped ceria electrolyte for IT-SOFCs by EDTA-citrate complexing method)